Otros idiomas Exelixis, Inc.

Acciones

EXEL

US30161Q1040

Tiempo real estimado Cboe BZX Otros sitios de cotización 16:58:27 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
23,54 ^USD	-0,80 %		+0,97 %	-1,98 %

11/04	EXELIXIS, INC. : Barclays es menos optimista	ZM
29/03	Jacqueline Wright notifica a Exelixis, Inc. su decisión de no presentarse a la reelección para el Consejo de Administración	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024	16/04
North American Morning Briefing : Big Banks Kick -2-	12/04
Jacqueline Wright Notifies Exelixis, Inc. of Her Decision Not to Stand for Re-Election to the Board of Directors	29/03
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March	27/02
BioInvent International AB Year-end report January 1, December 31, 2023	23/02
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing	22/02
BioInvent International AB Year-end report January 1 – December 31, 2023	22/02
Exelixis Swings to Earnings in Fiscal Q4 as Sales Increase; 2024 Revenue Guidance Set	06/02
Exelixis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/02
Exelixis: Q4 Earnings Snapshot	06/02
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024	06/02
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update	06/02
Earnings Flash (EXEL) EXELIXIS Reports Q4 Revenue $480M, vs. Street Est of $477.9M	06/02
Earnings Flash (EXEL) EXELIXIS Posts Q4 EPS $0.33, vs. Street Est of $0.31	06/02
Exelixis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/02
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February	01/02
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024	25/01
Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024	25/01
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024	23/01
Bristol Myers Squibb - Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits after Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma	23/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Exelixis, Inc.

Acciones

EXEL

US30161Q1040

Otros idiomas

Filtros